EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, AIM Vaccine Co's enterprise value is HK$10,101 Mil.
AIM Vaccine Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-2,245 Mil. Therefore, AIM Vaccine Co's EV-to-EBITDA for today is -4.50.
The historical rank and industry rank for AIM Vaccine Co's EV-to-EBITDA or its related term are showing as below:
HKSE:06660'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -245.57 Med: -55.39 Max: -4.17
Current: -4.5
During the past 5 years, the highest EV-to-EBITDA of AIM Vaccine Co was -4.17. The lowest was -245.57. And the median was -55.39.
HKSE:06660's EV-to-EBITDA is ranked worse than 100% of 450
companies
in the Biotechnology industry
Industry Median: 9.57
vs HKSE:06660: -4.50
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
AIM Vaccine Co EV-to-EBITDA Historical Data
The historical data trend for AIM Vaccine Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of AIM Vaccine Co's EV-to-EBITDA
For the Biotechnology subindustry, AIM Vaccine Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AIM Vaccine Co's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AIM Vaccine Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where AIM Vaccine Co's EV-to-EBITDA falls into.
AIM Vaccine Co EV-to-EBITDA Calculation
AIM Vaccine Co's EV-to-EBITDA for today is calculated as:
AIM Vaccine Co's current Enterprise Value is HK$10,101 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. AIM Vaccine Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-2,245 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AIM Vaccine Co (HKSE:06660) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
AIM Vaccine Co's PE Ratio for today is calculated as:
AIM Vaccine Co's share price for today is HK$7.43.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. AIM Vaccine Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1.171.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of AIM Vaccine Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
AIM Vaccine Co Ltd is a top full-chain vaccine corporation in China with businesses covering the whole industrial chain ranging from research and development, manufacturing and commercialization. The products available for sale mainly include Recombinant HBV vaccine, Human rabies vaccine, HFRS Vaccine, hepatitis A vaccine (human diploid cell), Group A, C, Y and W135 MPSV, mumps vaccine, freeze-dried human rabies vaccine (Vero cell) and ACYW135 meningococcal polysaccharide vaccine. Geographically, the company generates all of its revenues in the PRC.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:06660 has been successfully added to your